Alvotech(ALVO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.56 | Insider Own | 55.53% | Shs Outstand | 356.8M | Perf Week | -5.08% |
| Market Cap | 1.97B | Forward P/E | 22.26 | EPS next Y | 1620.02% | Insider Trans | - | Shs Float | 173.6M | Perf Month | 23.47% |
| Enterprise Value | 3.28B | PEG | - | EPS next Q | -0.02 | Inst Own | 11.05% | Short Float | 3.22% | Perf Quarter | 21.1% |
| Income | -0.18B | P/S | 4.01 | EPS this Y | 85.07% | Inst Trans | 8.02% | Short Ratio | 5.99 | Perf Half Y | 45.53% |
| Sales | 0.49B | P/B | - | EPS next 5Y | - | ROA | -12.05% | Short Interest | 5.59M | Perf YTD | -1.56% |
| Book/sh | -0.54 | P/C | 13.81 | EPS past 3/5Y | - | ROE | - | 52W High | -45.41% ($9.25) | Perf Year | -37.11% |
| Cash/sh | 0.37 | P/FCF | - | Sales past 3/5Y | 91.85% - | ROIC | -14.88% | 52W Low | 71.77% ($2.94) | Perf 3Y | -42.61% |
| Dividend Est. | - | EV/EBITDA | 38.06 | EPS Y/Y TTM | -365.51% | Gross Margin | 60.45% | Volatility(W/M) | 3.57% 5.61% | Perf 5Y | -48.63% |
| Dividend TTM | - | EV/Sales | 6.67 | Sales Y/Y TTM | -12.17% | Oper. Margin | 9.12% | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.96 | EPS Q/Q | -276.37% | Profit Margin | -36.51% | RSI (14) | 59.69 | Recom | 1.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.65 | Sales Q/Q | -38.94% | SMA20 | 3.05% ($4.9) | Beta | 0.22 | Target Price | $6.46 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/19 | SMA50 | 23.57% ($4.09) | Rel Volume | 0.72 | Prev Close | $5.29 |
| Employees | 1460 | LT Debt/Eq | - | EPS/Sales Surpr. | -62.17% 2.91% | SMA200 | 21.71% ($4.15) | Avg Volume(3M) | 0.93M | Price | $5.05 |
| IPO | 2020/11/9 | Option/Short | No/Yes | Trades | 4264 | Volume | 674,194 | Change | -4.54% |
Company
ALVO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Alvotech is a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of biosimilars (generic versions of biologic medicines). The company supplies lower-cost alternatives to high-priced original biologic drugs in specialty therapeutic areas such as immunology and oncology. With a fully integrated, single platform spanning R&D, manufacturing, regulatory affairs, and device assembly, Alvotech highlights its deep technical expertise and faster development speed as key advantages over traditional pharmaceutical companies that treat biosimilars as a side business.
Over the past 1 year, roughly in the middle
45% below its 1-year high.
ALVO has weak earning power
9.12% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +85.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -42.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 11.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
GLCR 0.05%
IDNA 0.00%
IBBQ 0.00%
BIB 0.00%
IBB 0.00%It ranks #4 in the industry
Based on market cap of $2B.
ALVO $2B PER -
TAK $59B PER -
TEVA $45B PER 64.5
HLN $41B PER 19.3
FAQ
What kind of company is ALVO?
ALVO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ALVO?
The market cap of ALVO is approximately $2.0B, ranking 2,114 within its sector.
What is the 52-week high and low for ALVO?
ALVO has recorded a 52-week high of $9.25 and a low of $2.94.
